Sonskyn Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 31.54%
- Profit Growth 126.59%
- Ebitda 126.64%
- Net Worth 55.19%
- Total Assets 23.28%
About Sonskyn Pharmaceuticals
Sonskyn Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 April 2016 (Eight years and nine months 20 days old ). Its registered office is in Indira Nagar, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ragini Tripathi and Sheel Tripathi serve as directors at the Company.
Company Details
-
Location
Indira Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24129UP2016PTC082633
-
Company No.
082633
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Apr 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Sonskyn Pharmaceuticals Private Limited offer?
Sonskyn Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Fitness Supplements, Nutritional Supplements.
Who are the key members and board of directors at Sonskyn Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sheel Tripathi
|
Director | 22-Apr-2016 | Current |
|
Ragini Tripathi
|
Director | 09-Nov-2017 | Current |
Financial Performance of Sonskyn Pharmaceuticals.
Sonskyn Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.54% increase. The company also saw a substantial improvement in profitability, with a 126.59% increase in profit. The company's net worth Soared by an impressive increase of 55.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sonskyn Pharmaceuticals?
In 2023, Sonskyn Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sonskyn Pharmaceuticals?
Unlock and access historical data on people associated with Sonskyn Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sonskyn Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sonskyn Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
